All Stories

  1. Peptide epitopes of NC16A BP180 in the diagnostics of bullous pemphigoid.
  2. The Role of Microbiota in the Pathogenesis of Bullous Pemphigoid and Pemphigus Vulgaris: Evidence, Controversies, and Perspectives
  3. Medical Nutrition Therapy in Dermatological Diseases: A Joint Consensus Statement of the Italian Association of Dietetics and Clinical Nutrition (ADI), the Italian Society of Dermatology and Sexually Transmitted Diseases (SIDeMaST), the Italian Society...
  4. Exploring the Gut Microbiota–Retina Axis: Implications for Health and Disease
  5. Off-label use of tralokinumab in the treatment of bullous pemphigoid: a case series
  6. Management of Bullous Pemphigoid in Special Populations: A Narrative Review of the Literature
  7. It is time to reconsider antibodies against integrin β4 in mucous membrane pemphigoid: Comment on ‘Native collagen XVII complex ELISA: An approach for diagnosis and monitoring of anti‐integrin β4 mucous membrane pemphigoid’
  8. Posidonia oceanica (L.) Delile Is a Promising Marine Source Able to Alleviate Imiquimod-Induced Psoriatic Skin Inflammation
  9. S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology
  10. Reply to ‘Comments on the first European guideline for paraneoplastic autoimmune multiorgan syndrome’
  11. Hydroxychloroquine-induced generalized myopathy in a patient with lupus tumidus: a case report
  12. Impact of COVID‐19 in patients with autoimmune bullous diseases: Report from an international registry
  13. Oral and Topical Probiotics and Postbiotics in Skincare and Dermatological Therapy: A Concise Review
  14. Tralokinumab efficacy in a case of dupilumab‐resistant severe atopic dermatitis complicated by eczema herpeticum
  15. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology ( EADV )
  16. Lepromatous leprosy presenting with erythema nodosum leprosum mimicking Bechet's disease
  17. Severe bullous pemphigoid following Covid‐19 vaccination resistant to rituximab and successfully treated with dupilumab
  18. Rituximab in Mucous Membrane Pemphigoid: A Monocentric Retrospective Study in 10 Patients with Severe/Refractory Disease
  19. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology ( EADV )
  20. Sweet Syndrome Following SARS-CoV2 Vaccination
  21. Development and optimisation of biopharmaceutical properties of a new microemulgel of cannabidiol for locally-acting dermatological delivery
  22. S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)
  23. Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy
  24. The Role of TRPA1 in Skin Physiology and Pathology
  25. T-Cell Response in Dermatitis Herpetiformis: May Epidermal Transglutaminase Play a Role in Predicting Clinical Relapse?
  26. Female Patients with Dermatitis Herpetiformis Show a Reduced Diagnostic Delay and Have Higher Sensitivity Rates at Autoantibody Testing for Celiac Disease
  27. Cutaneous eruptions associated with haematologic malignancies: the need for a unifying nomenclature
  28. Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study
  29. T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum
  30. A fatal case of hidradenitis suppurativa associated with sepsis and squamous cell carcinoma
  31. Docetaxel-induced-like subacute cutaneous lupus erythematosus
  32. Corrigendum
  33. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum
  34. The diagnosis and treatment of dermatitis herpetiformis
  35. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group
  36. A case of rupioid psoriasis exacerbated by systemic glucocorticosteroids
  37. Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris
  38. Regulatory T cells as well as IL-10 are reduced in the skin of patients with dermatitis herpetiformis
  39. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome
  40. Dermatitis Herpetiformis: Not Only in Adults
  41. Skin manifestations of celiac disease: not always dermatitis herpetiformis
  42. Rowell syndrome: does it exist?
  43. Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid
  44. Neo-epitope tissue transglutaminase autoantibodies as a biomarker of the gluten sensitive skin disease — Dermatitis herpetiformis
  45. Linear Immunoglobulin A Bullous Dermatosis: Need for an Agreement on Diagnostic Criteria
  46. Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)
  47. A further case of subacute prurigo-like linear IgA bullous dermatosis: growing evidence of a new subset
  48. Hailey-Hailey disease treated with methotrexate
  49. Etanercept Downregulates the Th17 Pathway and Decreases the IL-17+/IL-10+ Cell Ratio in Patients with Psoriasis Vulgaris
  50. Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients
  51. Newly Described Clinical and Immunopathological Feature of Dermatitis Herpetiformis
  52. Dermatitis herpetiformis: Novel advances and hypotheses
  53. Dermatitis Herpetiformis: From the Genetics to the Development of Skin Lesions
  54. Celiac Disease and Dermatologic Manifestations: Many Skin Clue to Unfold Gluten-Sensitive Enteropathy
  55. The last word on the so-called ‘Rowell’s syndrome’?
  56. Gluten-Free Diet in Patients With Dermatitis Herpetiformis: Not Only a Matter of Skin
  57. Comment on "Dermatitis Herpetiformis Sera or Goat Anti-Transglutaminase-3 Transferred to Human Skin-Grafted Mice Mimics Dermatitis Herpetiformis Immunopathology"
  58. A case of lichenoid drug eruption associated with subcutaneous immunoglobulin therapy
  59. Serum levels of the regulatory cytokines transforming growth factor-β and interleukin-10 are reduced in patients with discoid lupus erythematosus
  60. Repigmentation of hair after latanoprost therapy
  61. Characterization of regulatory T cells in patients with dermatomyositis
  62. Effects of tacrolimus ointment on Toll-like receptors in atopic dermatitis
  63. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea
  64. Immunosuppressive therapy may affect the number of circulating regulatory cells in systemic sclerosis: Pay attention to the patient selection criteria
  65. Linear immunoglobulin A bullous dermatosis
  66. Plasma levels of metalloproteinase-9 are elevated in patients with chronic autoimmune urticaria
  67. Antilaminin-1 antibodies in cutaneous lupus erythematosus patients
  68. Guidelines for the diagnosis and treatment of dermatitis herpetiformis
  69. A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis
  70. Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial
  71. Serum interleukin-13 levels are increased in patients with Stevens–Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme
  72. FoxP3-expressing T regulatory cells in atopic dermatitis lesions
  73. The CD40/CD40 ligand system is involved in the pathogenesis of pemphigus
  74. Chronic autoimmune urticaria in a patient with multiple piloleiomyomas
  75. Cutis marmorata telangiectatica congenita and chronic autoimmune urticaria in a young man
  76. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study
  77. Serum Levels of the Th1 Promoter IL-12 and the Th2 Chemokine TARC Are Elevated in Erythema Multiforme and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Correlate with Soluble Fas Ligand Expression
  78. Bullous pemphigoid initially localized around a urostomy
  79. Expression of adhesion molecules in atopic dermatitis is reduced by tacrolimus, but not by hydrocortisone butyrate: a randomized immunohistochemical study
  80. An unusual cause of gastrointestinal bleeding in a young girl
  81. Ulcerative Carcinoma of the Breast With Zosteriform Skin Metastases
  82. The Effects of Tacrolimus Ointment on Regulatory T Lymphocytes in Atopic Dermatitis
  83. Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum
  84. A Case of Nodular Scleroderma
  85. A Case of Lichenoid Drug Eruption Associated with Sildenafil Citratus
  86. Radiation Therapy as a Trigger Factor for Initially Localized Bullous Pemphigoid
  87. Serological detection of eotaxin, IL-4, IL-13, IFN-γ, MIP-1α, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria
  88. Chronic Idiopathic and Chronic Autoimmune Urticaria: Clinical and Immunopathological Features of 68 Subjects
  89. Dermatite atopica: diagnostica in vitro